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A 48-year-old man presented with severe limb, bulbar, and respiratory weakness requiring
intubation and ventilation. Decrement was seen on repetitive nerve stimulation, but tested
muscles were too weak for voluntary activation and tetanic stimulation was not tolerated.
Positive voltage-gated calcium channel and SOX1 antibodies confirmed Lambert-Eaton
myasthenic syndrome (LEMS). Despite corticosteroids, 3,4-diaminopyridine, and plasma
exchange, severe bulbar weakness persisted, the patient remained tracheostomy-
dependent, and he developed marked tongue atrophy (figure, A). Small cell lung cancer
was subsequently confirmed. Radiotherapy 3 months after presentation resulted in recovery
of bulbar function, improvement in tongue atrophy, and tracheostomy decannulation with
improvement sustained 10 months later (figure, B and C). Tongue atrophy uncommonly
occurs in generalized myasthenia gravis1 but has not been previously reported in LEMS.
The underlying mechanism may be neurogenic atrophy due to severe neuromuscular
junction dysfunction.2
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Figure Patient photographs
(A) Two months after presentation with Lambert-Eaton myasthenic syndrome, inability to fully protrude tongue and
marked bilateral tongue atrophy is evident. (B) Threemonths later, 2months after radiotherapy to the patient’s small
cell lung tumor, onlymild atrophywas apparent with a triple furrowed appearance, and (C) normal tongue 10months
after radiotherapy.
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